A clinical trial involving leuprolide has been updated to completed status as of October 2, 2026. The study, registered as NCT03845751, is titled "EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control." It is a Phase 2 trial evaluating the combination of HIFU hemiablation with short term androgen deprivation therapy, which includes leuprolide, in prostate cancer control.
The trial status listed in the registry record is COMPLETED. This update reflects the current status of the study as recorded on ClinicalTrials.gov. No results or outcome data are included in this status update. The record does not state efficacy, safety findings, or conclusions related to the combination approach.
Leuprolide remains an approved compound. This trial update is procedural in nature, confirming that the Phase 2 study has concluded its active phase according to the registry. Readers interested in the broader context of this compound can consult the full trial record for further details as they become available.
For more background on leuprolide, including its approved uses and general profile, readers can refer to the compound overview.